Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Safety Panel: All MRI Gadolinium Contrast Agents Are Not Created Equal

Executive Summary

GE Healthcare's gadolinium MRI imaging contrast agent Omniscan stands to lose following a safety review by a joint FDA advisory committee, while rival products with a proven safety advantage could gain from the expert panel's recommendations
Advertisement

Related Content

FDA Contraindicates Three Gadolinium Imaging Agents In Severe Kidney Disease
FDA Contraindicates Three Gadolinium Imaging Agents In Severe Kidney Disease
Gadolinium Imaging Agents To Get Safety Review At FDA Advisory Committee
Gadolinium Imaging Agents To Get Safety Review At FDA Advisory Committee

Topics

Advertisement
UsernamePublicRestriction

Register

PS051762

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel